Literature DB >> 17880009

Likelihood of seizure remission in an adult population with refractory epilepsy.

Brian C Callaghan1, Kishlay Anand, Dale Hesdorffer, W Allen Hauser, Jacqueline A French.   

Abstract

OBJECTIVE: We aimed to determine the likelihood of remission and its clinical predictors in adult patients meeting a strict definition of refractory epilepsy. We also wanted to investigate the influence of treatment regimen on remission.
METHODS: A total of 246 patients with treatment refractory epilepsy (having at least 1 seizure per month and having not responded positively to at least 2 antiepileptic drugs) were identified in 2000 and followed for 3 years. We used Kaplan-Meier methods to estimate the rate of achieving a 6-month terminal seizure remission and Cox regression analysis to evaluate clinical predictors for seizure remission.
RESULTS: The estimated 6-month terminal seizure remission rate was 19% (95% confidence interval, 14-26%) for all cases and 14% (95% confidence interval, 10-21%) when limited to those treated only with medication. Negative predictors for remission included a history of status epilepticus, younger age at intractability, number of failed drug therapies, and presence of mental retardation. No specific drug was significantly associated with remission, and frequently, no clear intervention led to terminal remission.
INTERPRETATION: Fifteen percent (approximately 5% per year) of a drug refractory epilepsy population obtained a 6-month terminal seizure remission. Our results signify that no matter how many antiepileptic drug therapies have failed, there is always hope of a meaningful seizure remission in this population. Furthermore, we have elucidated four clinical predictors that can aid the epileptologist in prognostication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880009     DOI: 10.1002/ana.21166

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  65 in total

1.  Intractable epilepsy: relapsing, remitting, or progressive?

Authors:  Susan Herman
Journal:  Epilepsy Curr       Date:  2010-11       Impact factor: 7.500

2.  New developments in antiepileptic drug resistance: an integrative view.

Authors:  Dieter Schmidt; Wolfgang Löscher
Journal:  Epilepsy Curr       Date:  2009 Mar-Apr       Impact factor: 7.500

3.  Confusing placebo effect with natural history in epilepsy: A big data approach.

Authors:  Daniel M Goldenholz; Robert Moss; Jonathan Scott; Sungyoung Auh; William H Theodore
Journal:  Ann Neurol       Date:  2015-07-29       Impact factor: 10.422

Review 4.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

5.  Seizure remission in adults with intractable epilepsy: not just a pipe dream.

Authors:  Paul Garcia
Journal:  Epilepsy Curr       Date:  2008 Jul-Aug       Impact factor: 7.500

6.  Epilepsy: Guidelines on vagus nerve stimulation for epilepsy.

Authors:  Patricia Dugan; Orrin Devinsky
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 7.  Prognosis of intractable epilepsy: is long-term seizure freedom possible with medical management?

Authors:  Heidi Munger Clary; Hyunmi Choi
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

Review 8.  Genetic biomarkers in epilepsy.

Authors:  Yvonne G Weber; Anne T Nies; Matthias Schwab; Holger Lerche
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 9.  [Medical treatment of epilepsy: hidden dimensions].

Authors:  J Bauer; C Kronisch
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

Review 10.  Management of the patient with medically refractory epilepsy.

Authors:  Tiziana Granata; Nicola Marchi; Erin Carlton; Chaitali Ghosh; Jorge Gonzalez-Martinez; Andreas V Alexopoulos; Damir Janigro
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.